| 12.16 -0.02 (-0.16%) | 11-06 09:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.3 |
1-year : | 16.7 |
| Resists | First : | 12.24 |
Second : | 14.3 |
| Pivot price | 10.62 |
|||
| Supports | First : | 9.98 |
Second : | 8.57 |
| MAs | MA(5) : | 11.17 |
MA(20) : | 10.31 |
| MA(100) : | 8.25 |
MA(250) : | 7.63 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 70.8 |
| RSI | RSI(14): 73.2 |
|||
| 52-week | High : | 12.24 | Low : | 4.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CERT ] has closed above the upper band by 2.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 89.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.26 - 12.31 | 12.31 - 12.36 |
| Low: | 10.71 - 10.76 | 10.76 - 10.8 |
| Close: | 12.1 - 12.18 | 12.18 - 12.28 |
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Fri, 06 Nov 2026
Why Did Certara (CERT) Shares Climb After Its Latest Update? - Yahoo Finance
Fri, 06 Nov 2026
Key facts: Certara Bookings Up 4%; Losses Widen; Phoenix Cloud 10% - TradingView
Thu, 05 Nov 2026
Certara, Inc. (CERT) stock price, news, quote and history - Yahoo Finance Singapore
Thu, 05 Nov 2026
Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand - Yahoo Finance
Thu, 05 Nov 2026
Certara (CERT) Q3 2026 Earnings Call Transcript - The Globe and Mail
Thu, 05 Nov 2026
Certara Q3 2026 Earnings Call Transcript - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 153 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 111 (%) |
| Shares Short | 27,700 (K) |
| Shares Short P.Month | 28,970 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.34 |
| Profit Margin | -16.3 % |
| Operating Margin | -0.3 % |
| Return on Assets (ttm) | 0.7 % |
| Return on Equity (ttm) | -2.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 1.7 |
| Sales Per Share | 2.76 |
| EBITDA (p.s.) | 0.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 83 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | -87 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 4.4 |
| Price to Cash Flow | 22.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|